• Search
      • Search Interactions Search Categories
    • Browse
      • Browse Categories Browse Sources
    • Information
      • About Publications Interaction Types & Directionalities Interaction Score & Query Score API Documentation FAQ Known Data Clients News Contact
    • Downloads
      • Data Source Code

HALOPERIDOL Drug Record

  • Summary
  • Interactions
  • Claims
  • HALOPERIDOL chembl:CHEMBL54 Approved

    Alternate Names:

    DOLPIN
    KENTACE
    DOZIC
    MCN-JR-1625
    R-1625
    NSC-170973
    HALDOL SOLUTAB
    NSC-615296
    FORTUNAN
    HALDOL
    SERENACE
    KESELEN
    HALOPERIDOL
    SERENACE®
    GAMMA-(4-(P-CHLOROPHENYL)-4-HYDROXPIPERIDINO)-P-FLUORBUTYROPHENONE
    4-[4-(4-CHLOROPHENYL)-4-HYDROXY-1-PIPERIDYL]-1-(4-FLUOROPHENYL)-BUTAN-1-ONE
    4'-FLUORO-4-(4-(P-CHLOROPHENYL)-4-HYDROXYPIPERIDINYL)BUTYROPHENONE
    HALDOL®
    HALOPERIDOLUM
    Γ-(4-(P-CHLOROPHENYL)-4-HYDROXPIPERIDINO)-P-FLUORBUTYROPHENONE
    4'-FLUORO-4-(4-HYDROXY-4-(4'-CHLOROPHENYL)PIPERIDINO)BUTYROPHENONE
    4-(4-(PARA-CHLOROPHENYL)-4-HYDROXYPIPERIDINO)-4'-FLUOROBUTYROPHENONE
    1-(3-P-FLUOROBENZOYLPROPYL)-4-P-CHLOROPHENYL-4-HYDROXYPIPERIDINE
    chemidplus:52-86-8
    pubchem.compound:3559
    rxcui:5093
    drugbank:00502
    chembl:CHEMBL54

    Drug Info:

    Year of Approval 1967
    Drug Class antipsychotic agents
    FDA Approval 1967
    Drug Class small molecule
    Drug Indications Antipsychotic Agents
    (4 More Sources)

    Publications:

    Porcelli S et al., 2016, Possible biomarkers modulating haloperidol efficacy and/or tolerability., Pharmacogenomics
    Zanger UM et al., 2008, Functional pharmacogenetics/genomics of human cytochromes P450 involved in drug biotransformation., Anal Bioanal Chem
    Eastwood et al., 1996, The effect of chronic haloperidol treatment on glutamate receptor subunit (GluR1, GluR2, KA1, KA2, NR1) mRNAs and glutamate binding protein mRNA in rat forebrain., Neurosci. Lett.
    Ishiwata et al., 2006, A feasibility study of [11C]SA4503-PET for evaluating sigmal receptor occupancy by neuroleptics: the binding of haloperidol to sigma1 and dopamine D2-like receptors., Ann Nucl Med
    Leysen et al., 1994, Risperidone: a novel antipsychotic with balanced serotonin-dopamine antagonism, receptor occupancy profile, and pharmacologic activity., J Clin Psychiatry
    Bustillo et al., 2006, Long-term treatment of rats with haloperidol: lack of an effect on brain N-acetyl aspartate levels., Neuropsychopharmacology
    Naiker et al., 2006, Dose determination of haloperidol, risperidone and olanzapine using an in vivo dopamine D2-receptor occupancy method in the rat., Eur. J. Pharmacol.
    Osinski et al., 2005, Dopamine D2, but not D4, receptor agonists are emetogenic in ferrets., Pharmacol. Biochem. Behav.
    Seeman, 2010, Dopamine D2 receptors as treatment targets in schizophrenia., Clin Schizophr Relat Psychoses
    Uchida et al., 2007, Brain neurotransmitter receptor-binding characteristics in rats after oral administration of haloperidol, risperidone and olanzapine., Life Sci.
    Chen et al., 2002, TTD: Therapeutic Target Database., Nucleic Acids Res.
    Lipska et al., 2003, Gene expression in dopamine and GABA systems in an animal model of schizophrenia: effects of antipsychotic drugs., Eur. J. Neurosci.
    Tresadern G et al., 2011, Molecular properties affecting fast dissociation from the D2 receptor., Bioorg Med Chem
    Jönsson EG et al., 1999, Polymorphisms in the dopamine D2 receptor gene and their relationships to striatal dopamine receptor density of healthy volunteers., Mol Psychiatry
    Pohjalainen T et al., 1998, The A1 allele of the human D2 dopamine receptor gene predicts low D2 receptor availability in healthy volunteers., Mol Psychiatry
    Monteleone P et al., 2009, Management of schizophrenia with obesity, metabolic, and endocrinological disorders., Psychiatr Clin North Am
    Hoenicka J et al., 2010, The ANKK1 gene associated with addictions is expressed in astroglial cells and upregulated by apomorphine., Biol Psychiatry
    Blum K et al., 1990, Allelic association of human dopamine D2 receptor gene in alcoholism., JAMA
    Kraschewski A et al., 2009, Association of the dopamine D2 receptor gene with alcohol dependence: haplotypes and subgroups of alcoholics as key factors for understanding receptor function., Pharmacogenet Genomics
    Liu YZ et al., 2009, Association of the DRD2 and DRD3 polymorphisms with response to pramipexole in Parkinson's disease patients., Eur J Clin Pharmacol
    Doehring A et al., 2009, Genetic variants altering dopamine D2 receptor expression or function modulate the risk of opiate addiction and the dosage requirements of methadone substitution., Pharmacogenet Genomics
    Munafò MR et al., 2009, Lack of association of DRD2 rs1800497 (Taq1A) polymorphism with smoking cessation in a nicotine replacement therapy randomized trial., Nicotine Tob Res
    Le Foll B et al., 2009, Genetics of dopamine receptors and drug addiction: a comprehensive review., Behav Pharmacol
    Shen YC et al., 2009, Effects of DRD2/ANKK1 gene variations and clinical factors on aripiprazole efficacy in schizophrenic patients., J Psychiatr Res
    Ikeda M et al., 2008, Variants of dopamine and serotonin candidate genes as predictors of response to risperidone treatment in first-episode schizophrenia., Pharmacogenomics
    David SP et al., 2008, Genetic variation in the dopamine pathway and smoking cessation., Pharmacogenomics
    Thelma B et al., 2008, Genetic underpinnings of tardive dyskinesia: passing the baton to pharmacogenetics., Pharmacogenomics
    Blum K et al., 1991, Association of the A1 allele of the D2 dopamine receptor gene with severe alcoholism., Alcohol
    Huang W et al., 2009, Significant association of ANKK1 and detection of a functional polymorphism with nicotine dependence in an African-American sample., Neuropsychopharmacology
    Bakker PR et al., 2008, Antipsychotic-induced tardive dyskinesia and polymorphic variations in COMT, DRD2, CYP1A2 and MnSOD genes: a meta-analysis of pharmacogenetic interactions., Mol Psychiatry
    Alenius M et al., 2008, Gene polymorphism influencing treatment response in psychotic patients in a naturalistic setting., J Psychiatr Res
    Smith L et al., 2008, Meta-analysis of the association of the Taq1A polymorphism with the risk of alcohol dependency: a HuGE gene-disease association review., Am J Epidemiol
    Zai CC et al., 2007, Meta-analysis of two dopamine D2 receptor gene polymorphisms with tardive dyskinesia in schizophrenia patients., Mol Psychiatry
    Hwang R et al., 2005, Association study of 12 polymorphisms spanning the dopamine D(2) receptor gene and clozapine treatment response in two treatment refractory/intolerant populations., Psychopharmacology (Berl)
    Swan GE et al., 2005, Dopamine receptor DRD2 genotype and smoking cessation outcome following treatment with bupropion SR., Pharmacogenomics J
    Young et al., 2004, Prolactin levels in antipsychotic treatment of patients with schizophrenia carrying the DRD2*A1 allele., Br J Psychiatry
    Xu K et al., 2004, Association of specific haplotypes of D2 dopamine receptor gene with vulnerability to heroin dependence in 2 distinct populations., Arch Gen Psychiatry
    Neville MJ et al., 2004, Identification and characterization of ANKK1: a novel kinase gene closely linked to DRD2 on chromosome band 11q23.1., Hum Mutat
    Johnstone EC et al., 2004, Genetic variation in dopaminergic pathways and short-term effectiveness of the nicotine patch., Pharmacogenetics
    Ritchie T et al., 2003, Association of seven polymorphisms of the D2 dopamine receptor gene with brain receptor-binding characteristics., Neurochem Res
    Schäfer M et al., 2001, Association of short-term response to haloperidol treatment with a polymorphism in the dopamine D(2) receptor gene., Am J Psychiatry
    Suzuki A et al., 2000, The relationship between dopamine D2 receptor polymorphism at the Taq1 A locus and therapeutic response to nemonapride, a selective dopamine antagonist, in schizophrenic patients., Pharmacogenetics
    Mihara K et al., 2000, Prolactin response to nemonapride, a selective antagonist for D2 like dopamine receptors, in schizophrenic patients in relation to Taq1A polymorphism of DRD2 gene., Psychopharmacology (Berl)
    Kroeze et al., 2003, H1-histamine receptor affinity predicts short-term weight gain for typical and atypical antipsychotic drugs., Neuropsychopharmacology
    Cai et al., 1999, Inverse agonist properties of dopaminergic antagonists at the D(1A) dopamine receptor: uncoupling of the D(1A) dopamine receptor from G(s) protein., Mol. Pharmacol.
    Zhang JP et al., 2016, Pharmacogenetic Associations of Antipsychotic Drug-Related Weight Gain: A Systematic Review and Meta-analysis., Schizophr Bull
    Czerwensky F et al., 2013, MC4R rs489693: a clinical risk factor for second generation antipsychotic-related weight gain?, Int J Neuropsychopharmacol
    Nurmi EL et al., 2013, Moderation of antipsychotic-induced weight gain by energy balance gene variants in the RUPP autism network risperidone studies., Transl Psychiatry
    Malhotra AK et al., 2012, Association between common variants near the melanocortin 4 receptor gene and severe antipsychotic drug-induced weight gain., Arch Gen Psychiatry
    Sinor et al., 2000, NMDA and glutamate evoke excitotoxicity at distinct cellular locations in rat cortical neurons in vitro., J. Neurosci.
    Hattori et al., 2006, Fyn is required for haloperidol-induced catalepsy in mice., J. Biol. Chem.
    Steinmetz et al., 2002, A simple cell line based in vitro test system for N-methyl-D-aspartate (NMDA) receptor ligands., J. Neurosci. Methods
    Zhuravliova et al., 2007, Haloperidol induces neurotoxicity by the NMDA receptor downstream signaling pathway, alternative from glutamate excitotoxicity., Neurochem. Int.
    Gallagher et al., 1998, Modulation of the N-methyl-D-aspartate receptor by haloperidol: NR2B-specific interactions., J. Neurochem.
    Gu et al., 2007, Effects of (-)-stepholidine on NMDA receptors: comparison with haloperidol and clozapine., Acta Pharmacol. Sin.
    Kessler et al., 2005, Occupancy of striatal and extrastriatal dopamine D2/D3 receptors by olanzapine and haloperidol., Neuropsychopharmacology
    Malmberg et al., 1998, Agonist and inverse agonist activity at the dopamine D3 receptor measured by guanosine 5'--gamma-thio-triphosphate--35S- binding., J. Pharmacol. Exp. Ther.
    Tuppurainen et al., 2009, Dopamine D2/3 receptor binding potential and occupancy in midbrain and temporal cortex by haloperidol, olanzapine and clozapine., Psychiatry Clin. Neurosci.
    Tadori et al., 2008, Characterization of aripiprazole partial agonist activity at human dopamine D3 receptors., Eur. J. Pharmacol.
    Porcelli S et al., 2016, PDE7B, NMBR and EPM2A Variants and Schizophrenia: A Case-Control and Pharmacogenetics Study., Neuropsychobiology
    Obuchowicz et al., 2005, Alterations in striatal neuropeptide Y system activity of rats with haloperidol-induced behavioral supersensitivity., Neuropeptides
    de Bartolomeis et al., 2002, Acute administration of antipsychotics modulates Homer striatal gene expression differentially., Brain Res. Mol. Brain Res.
    Fernø et al., 2006, Drug-induced activation of SREBP-controlled lipogenic gene expression in CNS-related cell lines: marked differences between various antipsychotic drugs., BMC Neurosci
    Gilbert et al., 2006, Nur77 gene knockout alters dopamine neuron biochemical activity and dopamine turnover., Biol. Psychiatry
    O'Neill et al., 1998, Effects of 5-hydroxytryptamine2 receptor antagonism on the behavioral activation and immediate early gene expression induced by dizocilpine., J. Pharmacol. Exp. Ther.
    Hanson et al., 1981, Haloperidol-induced reduction of nigral substance P-like immunoreactivity: a probe for the interactions between dopamine and substance P neuronal systems., J. Pharmacol. Exp. Ther.
    Noh et al., 2000, Haloperidol-induced neuronal apoptosis: role of p38 and c-Jun-NH(2)-terminal protein kinase., J. Neurochem.
    Monteleone P et al., 2010, Endocannabinoid Pro129Thr FAAH functional polymorphism but not 1359G/A CNR1 polymorphism is associated with antipsychotic-induced weight gain., J Clin Psychopharmacol
    Tiwari AK et al., 2010, A common polymorphism in the cannabinoid receptor 1 (CNR1) gene is associated with antipsychotic-induced weight gain in Schizophrenia., Neuropsychopharmacology
    Zivković M et al., 2013, The association study of polymorphisms in DAT, DRD2, and COMT genes and acute extrapyramidal adverse effects in male schizophrenic patients treated with haloperidol., J Clin Psychopharmacol
    Dean et al., 2006, Regionally specific changes in levels of cortical S100beta in bipolar 1 disorder but not schizophrenia., Aust N Z J Psychiatry
    Hajipour AR et al., 2011, Electron-donating para-methoxy converts a benzamide-isoquinoline derivative into a highly Sigma-2 receptor selective ligand., Bioorg Med Chem
    Cobos EJ et al., 2007, Irreversible blockade of sigma-1 receptors by haloperidol and its metabolites in guinea pig brain and SH-SY5Y human neuroblastoma cells., J Neurochem
    Konkoy et al., 1996, Subchronic haloperidol administration decreases aminopeptidase N activity and [Met5]enkephalin metabolism in rat striatum and cortex., Eur. J. Pharmacol.
    Zheng M et al., 2015, The role of Abcb5 alleles in susceptibility to haloperidol-induced toxicity in mice and humans., PLoS Med
    Vázquez-Bourgon J et al., 2010, Serotonin transporter polymorphisms and early response to antipsychotic treatment in first episode of psychosis., Psychiatry Res
    Katchman AN et al., 2006, Comparative evaluation of HERG currents and QT intervals following challenge with suspected torsadogenic and nontorsadogenic drugs., J Pharmacol Exp Ther
    Celano et al., 2003, Selective regulation of presynaptic calcium/calmodulin-dependent protein kinase II by psychotropic drugs., Biol. Psychiatry
    Fang et al., 1995, Inhibition of monoamine oxidases by haloperidol and its metabolites: pharmacological implications for the chemotherapy of schizophrenia., Psychopharmacology (Berl.)
    Lara et al., 2001, Chronic treatment with clozapine, but not haloperidol, increases striatal ecto-5'-nucleotidase activity in rats., Neuropsychobiology
    Schmitt et al., 2003, Decreased gene expression of glial and neuronal glutamate transporters after chronic antipsychotic treatment in rat brain., Neurosci. Lett.
    Drago A et al., 2014, Genome-wide association study supports the role of the immunological system and of the neurodevelopmental processes in response to haloperidol treatment., Pharmacogenet Genomics
    Giegling I et al., 2011, Glutamatergic gene variants impact the clinical profile of efficacy and side effects of haloperidol., Pharmacogenet Genomics
    Chlan-Fourney et al., 2002, Differential regulation of hippocampal BDNF mRNA by typical and atypical antipsychotic administration., Brain Res.
    Heiser et al., 2006, Effects of different antipsychotics and the antidepressant mirtazapine on glucose transporter mRNA levels in human blood cells., J Psychiatr Res
  • HALOPERIDOL   SLC6A5

    Interaction Score: 2.9

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    27023437 20859245


    Sources:
    PharmGKB

  • HALOPERIDOL   ABCB5

    Interaction Score: 2.9

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    27023437 25647612


    Sources:
    PharmGKB

  • HALOPERIDOL   RGS2

    Interaction Score: 1.93

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    27023437


    Sources:
    PharmGKB

  • HALOPERIDOL   RTKN2

    Interaction Score: 1.93

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    27023437


    Sources:
    PharmGKB

  • HALOPERIDOL   TOR1A

    Interaction Score: 1.93

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    27023437


    Sources:
    PharmGKB

  • HALOPERIDOL   PLEKHA6

    Interaction Score: 1.93

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    27023437


    Sources:
    PharmGKB

  • HALOPERIDOL   ZIC4

    Interaction Score: 1.93

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    27023437


    Sources:
    PharmGKB

  • HALOPERIDOL   AKAP13

    Interaction Score: 1.93

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    27023437


    Sources:
    PharmGKB

  • HALOPERIDOL   HOMER1

    Interaction Score: 0.97

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    27023437


    Sources:
    PharmGKB

  • HALOPERIDOL   NKX6-1

    Interaction Score: 0.97

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    27023437


    Sources:
    PharmGKB

  • HALOPERIDOL   DPP6

    Interaction Score: 0.97

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    27023437


    Sources:
    PharmGKB

  • HALOPERIDOL   ARID5B

    Interaction Score: 0.97

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    27023437


    Sources:
    PharmGKB

  • HALOPERIDOL   DLG4

    Interaction Score: 0.97

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    11834303


    Sources:
    NCI

  • HALOPERIDOL   HSPG2

    Interaction Score: 0.64

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    27023437


    Sources:
    PharmGKB

  • HALOPERIDOL   IL1RN

    Interaction Score: 0.64

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    27023437


    Sources:
    PharmGKB

  • HALOPERIDOL   EIF2AK4

    Interaction Score: 0.48

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    27023437 24751813


    Sources:
    PharmGKB

  • HALOPERIDOL   DTNBP1

    Interaction Score: 0.48

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    27023437


    Sources:
    PharmGKB

  • HALOPERIDOL   GRIK4

    Interaction Score: 0.48

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    27023437


    Sources:
    PharmGKB

  • HALOPERIDOL   NPY

    Interaction Score: 0.39

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    16154634


    Sources:
    NCI

  • HALOPERIDOL   SLC1A1

    Interaction Score: 0.32

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    12873733


    Sources:
    NCI

  • HALOPERIDOL   HTR3E

    Interaction Score: 0.32

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    27023437


    Sources:
    PharmGKB

  • HALOPERIDOL   SIGMAR1

    Interaction Score: 0.32

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    22055714 17419803


    Sources:
    DTC

  • HALOPERIDOL   MC4R

    Interaction Score: 0.3

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    27217270 23920449 23799528 22566560


    Sources:
    PharmGKB

  • HALOPERIDOL   DRD2

    Interaction Score: 0.29

    Interaction Types & Directionality:
    inverse agonist (inhibitory)
    antagonist (inhibitory)

    Interaction Info:
    Direct Interaction yes
    Mechanism of Interaction D2-like dopamine receptor inverse agonist
    Trial Name -

    PMIDs:
    17134027 7520908 16132064 16730699 15894081 20643630 17316700 11752352 12887421 21421319 27023437 10395223 9672901 19944883 19853839 1969501 19603545 19396436 19373123 19273465 19179847 18926547 18855532 18781857 18781856 1839129 18354387 18180754 18086475 17989061 17767146 15830237 15492764 15286066 15184239 15146457 15077009 12587665 11329406 10862524 10823405 12629531


    Sources:
    DTC TdgClinicalTrial ChemblInteractions NCI TEND PharmGKB TTD

  • HALOPERIDOL   EPM2A

    Interaction Score: 0.28

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    27092952


    Sources:
    PharmGKB

  • HALOPERIDOL   NTS

    Interaction Score: 0.24

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    27023437


    Sources:
    PharmGKB

  • HALOPERIDOL   GRIN2B

    Interaction Score: 0.23

    Interaction Types & Directionality:
    antagonist (inhibitory)

    Interaction Info:

    PMIDs:
    11102491 16407246 11741727 17092607 9572299 17588330 11752352 27023437


    Sources:
    PharmGKB

  • HALOPERIDOL   NR4A1

    Interaction Score: 0.19

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    16893530


    Sources:
    NCI

  • HALOPERIDOL   ANPEP

    Interaction Score: 0.18

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    8851165


    Sources:
    NCI

  • HALOPERIDOL   ANKK1

    Interaction Score: 0.16

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    27023437


    Sources:
    PharmGKB

  • HALOPERIDOL   RYR1

    Interaction Score: 0.16

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    27023437


    Sources:
    PharmGKB

  • HALOPERIDOL   GRIA1

    Interaction Score: 0.16

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    8843098 27023437


    Sources:
    NCI PharmGKB

  • HALOPERIDOL   NT5E

    Interaction Score: 0.14

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    11490180


    Sources:
    NCI

  • HALOPERIDOL   CNR1

    Interaction Score: 0.12

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    23799528 20631561 20107430


    Sources:
    PharmGKB

  • HALOPERIDOL   CAMK2G

    Interaction Score: 0.11

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    12614997


    Sources:
    NCI

  • HALOPERIDOL   FAAH

    Interaction Score: 0.09

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    20631561


    Sources:
    PharmGKB

  • HALOPERIDOL   LDLR

    Interaction Score: 0.09

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    17052361


    Sources:
    NCI

  • HALOPERIDOL   COMT

    Interaction Score: 0.09

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    27023437 23963056


    Sources:
    PharmGKB

  • HALOPERIDOL   DRD3

    Interaction Score: 0.09

    Interaction Types & Directionality:
    inverse agonist (inhibitory)
    antagonist (inhibitory)

    Interaction Info:
    Mechanism of Interaction D2-like dopamine receptor inverse agonist
    Direct Interaction yes

    PMIDs:
    16123775 7520908 9536001 19496999 18831971


    Sources:
    ChemblInteractions

  • HALOPERIDOL   TAC1

    Interaction Score: 0.09

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    6166743


    Sources:
    NCI

  • HALOPERIDOL   GRIN2A

    Interaction Score: 0.06

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    27023437


    Sources:
    PharmGKB

  • HALOPERIDOL   HSPA4

    Interaction Score: 0.06

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    9864262


    Sources:
    NCI

  • HALOPERIDOL   CACNA1C

    Interaction Score: 0.06

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    27023437


    Sources:
    PharmGKB

  • HALOPERIDOL   HTR2C

    Interaction Score: 0.06

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    27023437 12629531


    Sources:
    PharmGKB

  • HALOPERIDOL   SLC6A4

    Interaction Score: 0.06

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    27023437 20031235


    Sources:
    PharmGKB

  • HALOPERIDOL   GRIN1

    Interaction Score: 0.05

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    27023437


    Sources:
    PharmGKB

  • HALOPERIDOL   SLC2A4

    Interaction Score: 0.04

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    16002093


    Sources:
    NCI

  • HALOPERIDOL   HTR3A

    Interaction Score: 0.04

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    27023437


    Sources:
    PharmGKB

  • HALOPERIDOL   MAOB

    Interaction Score: 0.04

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    7617809


    Sources:
    NCI

  • HALOPERIDOL   SLC6A3

    Interaction Score: 0.04

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    27023437


    Sources:
    PharmGKB

  • HALOPERIDOL   DRD1

    Interaction Score: 0.03

    Interaction Types & Directionality:
    antagonist (inhibitory)

    Interaction Info:

    PMIDs:
    10531405 11752352 27023437


    Sources:
    DTC PharmGKB

  • HALOPERIDOL   BDNF

    Interaction Score: 0.03

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    12393228


    Sources:
    NCI

  • HALOPERIDOL   HTR2A

    Interaction Score: 0.03

    Interaction Types & Directionality:
    other/unknown
    antagonist (inhibitory)

    Interaction Info:
    Mechanism of Interaction Serotonin 2a (5-HT2a) receptor antagonist
    Direct Interaction yes

    PMIDs:
    7520908 12629531


    Sources:
    ChemblInteractions

  • HALOPERIDOL   CYP3A5

    Interaction Score: 0.03

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    27023437 18695978


    Sources:
    PharmGKB

  • HALOPERIDOL   MAPK14

    Interaction Score: 0.03

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    11080184


    Sources:
    NCI

  • HALOPERIDOL   DRD4

    Interaction Score: 0.02

    Interaction Types & Directionality:
    inverse agonist (inhibitory)
    antagonist (inhibitory)

    Interaction Info:
    Mechanism of Interaction D2-like dopamine receptor inverse agonist
    Direct Interaction yes

    PMIDs:
    None found


    Sources:
    ChemblInteractions

  • HALOPERIDOL   KCNH2

    Interaction Score: 0.01

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    16278312


    Sources:
    DTC PharmGKB

  • HALOPERIDOL   MTOR

    Interaction Score: 0.01

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    DTC

  • HALOPERIDOL   TP53

    Interaction Score: 0.01

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    16476148


    Sources:
    NCI

  • HALOPERIDOL   ABCB1

    Interaction Score: 0.0

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    PharmGKB

  • HALOPERIDOL   GMNN

    Interaction Score: 0.0

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    DTC

  • HALOPERIDOL   CYP2D6

    Interaction Score: 0.0

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    DTC

  • HALOPERIDOL   AR

    Interaction Score: 0.0

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    DTC

  • HALOPERIDOL   CYP3A4

    Interaction Score: 0.0

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    DTC

  • TEND: HALOPERIDOL

    • Version: 01-August-2011

    Alternate Names:
    HALOPERIDOL Primary Drug Name

    Drug Info:
    Drug Class antipsychotic agents
    Year of Approval 1967

    Publications:

  • TdgClinicalTrial: HALOPERIDOL

    • Version: January-2014

    Alternate Names:

    Drug Info:
    Drug Indications Antipsychotic Agents
    Drug Class small molecule
    FDA Approval 1967

    Publications:

  • NCI: HALOPERIDOL

    • Version: 14-September-2017

    Alternate Names:
    C537 NCI drug code

    Drug Info:

    Publications:
    O'Neill et al., 1998, Effects of 5-hydroxytryptamine2 receptor antagonism on the behavioral activation and immediate early gene expression induced by dizocilpine., J. Pharmacol. Exp. Ther.
    Fang et al., 1995, Inhibition of monoamine oxidases by haloperidol and its metabolites: pharmacological implications for the chemotherapy of schizophrenia., Psychopharmacology (Berl.)
    Schmitt et al., 2003, Decreased gene expression of glial and neuronal glutamate transporters after chronic antipsychotic treatment in rat brain., Neurosci. Lett.

  • DTC: HALOPERIDOL

    • Version: 02-September-2020

    Alternate Names:
    CHEMBL54 ChEMBL Drug ID

    Drug Info:

    Publications:
    Hajipour AR et al., 2011, Electron-donating para-methoxy converts a benzamide-isoquinoline derivative into a highly Sigma-2 receptor selective ligand., Bioorg Med Chem
    Tresadern G et al., 2011, Molecular properties affecting fast dissociation from the D2 receptor., Bioorg Med Chem

  • PharmGKB: haloperidol

    • Version: 18-August-2020

    Alternate Names:

    Drug Info:

    Publications:
    Porcelli S et al., 2016, Possible biomarkers modulating haloperidol efficacy and/or tolerability., Pharmacogenomics
    Zanger UM et al., 2008, Functional pharmacogenetics/genomics of human cytochromes P450 involved in drug biotransformation., Anal Bioanal Chem
    Zheng M et al., 2015, The role of Abcb5 alleles in susceptibility to haloperidol-induced toxicity in mice and humans., PLoS Med

  • TTD: Haloperidol

    • Version: 2020.06.01

    Alternate Names:
    D0D1AL TTD Drug ID

    Drug Info:

    Publications:

  • ChemblDrugs: chembl:CHEMBL54

    • Version: ChEMBL_27

    Alternate Names:

    Drug Info:

    Publications:

  • ChemblInteractions: CHEMBL54

    • Version: chembl_23

    Alternate Names:

    Drug Info:

    Publications:

Disclaimer: This resource is intended for purely research purposes. It should not be used for emergencies or medical or professional advice.

A finding of a drug-gene interaction or potentially druggable category does not necessarily indicate effectiveness (or lack thereof) of any drug or treatment regimen. A finding of no interaction or no potentially druggable category does not necessarily indicate lack of effectiveness of any drug or treatment regimen. Drug-gene interactions or potentially druggable categories are not presented in ranked order of potential or predicted efficacy.

The dgidb.org website does not provide any medical or healthcare products, services or advice, and is not for medical emergencies or urgent situations. IF YOU THINK YOU MAY HAVE A MEDICAL EMERGENCY, CALL YOUR DOCTOR OR 911 IMMEDIATELY. Information contained on this website is not a substitute for a doctor's medical judgment or advice. We recommend that you discuss your specific, individual health concerns with your doctor or health care professional.

DGIdb (v4.2.0 - sha1 afd9f30b) • Last updated 2020-10-21